The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Abstract
PURPOSE: The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied. METHODS: Two randomized, single-blind, placebo-controlled studies were conducted. Treatment with oral antidiabetic agents was stopped 14 days before study initiation. In the first study (study A), eight subjects received placebo, 0.1-, 0.2-, 0.3-, and either 0.4-microg/kg exenatide or placebo five minutes before a meal combined with liquid acetaminophen (to assess the rate of gastric emptying) on days 1, 3, 5, 7, and 9. In the second study (study B), subjects received a single s.c. dose of exenatide or placebo on consecutive days. Part 1 of study B used exenatide doses of 0.01 and 0.1 microg/ kg; 0.02-, 0.05-, and 0.1-microg/kg doses were given in part 2. After an overnight fast, the study drug was injected 15 minutes before a meal (part 1) and before a meal and acetaminophen (part 2). Parts 1 and 2 of study B enrolled six and eight patients, respectively. RESULTS: In both studies, plasma exenatide pharmacokinetic profiles appeared dose proportional. Exenatide doses of 0.02-0.2 microg/kg dose-dependently lowered postprandial glucose excursions. Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying. There were no serious adverse events and no patient withdrawals related to treatment. Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 microg/kg. CONCLUSION: Administration of preprandial exenatide by s.c. injection resulted in dose-proportional exenatide pharmacokinetics and antidiabetic pharmacodynamic activity. At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma glucose excursion by insulinotropism, suppression of plasma glucagon, and slowing of gastric emptying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Racial and ethnic differences in glycemic control of adults with type 2 diabetes.
Harris, M. I., Eastman, R. C., Cowie, C. C., Flegal, K. M., & Eberhardt, M. S. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.403 · Cited by 646
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Self-citationRelationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
Rayner, C. K., Samsom, M., Jones, K. L., & Horowitz, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.371 · Cited by 460
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Kinetics of acetaminophen absorption and gastric emptying in man
Clements, J. A., Heading, R. C., Nimmo, W. S., & Prescott, L. F. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978244420 · Cited by 369
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353
Self-citationExendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256
The Effect of Acute Hyperglycemia on Gastric Emptying in Man
MacGregor, I. L., Gueller, R., Watts, H. D., & Meyer, J. H. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80008-x · Cited by 249
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241
Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment
Mahler, R. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1165 · Cited by 202
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 166
Implications of the United Kingdom Prospective Diabetes Study
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s28 · Cited by 163
Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158
Mallinckrodt, C. H., Clark, W. S., Carroll, R. J., & Molenberghs, G. (2003) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120019265 · Cited by 138
Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.
Nielsen, L. L., & Baron, A. (2003) · PubMed · Cited by 82
Self-citationGreen, G. M., Guan, D., Schwartz, J. G., & Phillips, W. T. (1997) · Diabetologia · doi:10.1007/s001250050654 · Cited by 34
Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms
Moore, M., & Cherrington, A. (1996) · annales de biologie animale biochimie biophysique · doi:10.1051/rnd:19960406 · Cited by 18
Research works printed but not linked: 6
- 2002, J Clin Endocrinol Metab, 87, 1282, 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- 2000, Endocrinology, 141, 1936, 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
- 2003, Curr Opin Investig Drugs, 4, 401
- 1999, J Clin Endocrinol Metab, 84, 1165, 10.1210/jcem.84.4.5612 · doi:10.1210/jcem.84.4.5612 · Paper page
- 1996, Diabet Med, 13, S34, 10.1002/dme.1996.13.s1.34 · doi:10.1002/dme.1996.13.s1.34
- 1987, Surg Gynecol Obstet, 165, 41
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Metadata
- Authors
- Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-15
- Volume
- 62
- Issue
- 2
- Pages
- 173-181
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2344620176
- Cited by
- 434
- References
- 32
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.